Literature DB >> 15483652

Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.

Mark Nellist1, Ozgur Sancak, Miriam A Goedbloed, Christan Rohe, Diana van Netten, Karin Mayer, Aimee Tucker-Williams, Ans M W van den Ouweland, Dicky J J Halley.   

Abstract

Tuberous sclerosis is an autosomal dominant human disorder caused by inactivating mutations to either the TSC1 or TSC2 tumour suppressor gene. Hamartin and tuberin, the TSC1 and TSC2 gene products, interact and the tuberin-hamartin complex inhibits cell growth by antagonising signal transduction to downstream effectors of the mammalian target of rapamycin (mTOR) through the small GTPase rheb. Previously, we showed that pathogenic tuberin amino-acid substitutions disrupt the tuberin-hamartin complex. Here, we investigate how these mutations affect the role of tuberin in the control of signal transduction through mTOR. Our data indicate that specific amino-acid substitutions have distinct effects on tuberin function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15483652     DOI: 10.1038/sj.ejhg.5201276

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  34 in total

Review 1.  Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex.

Authors:  Petrus J de Vries
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 2.  Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak; Tomasz Grzela; Maciej Lazarczyk
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

3.  Genetics and neuropsychiatric disorders: genome-wide, yet narrow.

Authors:  Petrus J de Vries
Journal:  Nat Med       Date:  2009-08       Impact factor: 53.440

4.  Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.

Authors:  Suchithra Menon; Christian C Dibble; George Talbott; Gerta Hoxhaj; Alexander J Valvezan; Hidenori Takahashi; Lewis C Cantley; Brendan D Manning
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

5.  A reliable cell-based assay for testing unclassified TSC2 gene variants.

Authors:  Ricardo Coevoets; Sermin Arican; Marianne Hoogeveen-Westerveld; Erik Simons; Ans van den Ouweland; Dicky Halley; Mark Nellist
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

6.  mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.

Authors:  Lena H Nguyen; Travorn Mahadeo; Angélique Bordey
Journal:  J Neurosci       Date:  2019-01-30       Impact factor: 6.167

7.  WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase.

Authors:  Jian Hu; Sima Zacharek; Yizhou Joseph He; Hyun Lee; Stuart Shumway; Robert J Duronio; Yue Xiong
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

Review 8.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

9.  Genetics and molecular biology of tuberous sclerosis complex.

Authors:  Valerio Napolioni; Paolo Curatolo
Journal:  Curr Genomics       Date:  2008-11       Impact factor: 2.236

10.  Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex.

Authors:  Melika Mozaffari; Marianne Hoogeveen-Westerveld; David Kwiatkowski; Julian Sampson; Rosemary Ekong; Sue Povey; Johan T den Dunnen; Ans van den Ouweland; Dicky Halley; Mark Nellist
Journal:  BMC Med Genet       Date:  2009-09-11       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.